The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of pretreatment p63-positive subtype of gastroesophageal adenocarcinoma (GEAC) with pathologic complete response (pathCR) in patients receiving preoperative chemoradiation.
 
Elena Elimova
Employment - Merck (I)
 
Soo-Mi Kim
No Relationships to Disclose
 
Xuemei Wang
No Relationships to Disclose
 
Yusuke Shimodaira
No Relationships to Disclose
 
Bo Hwa Sohn
No Relationships to Disclose
 
Heath Devin Skinner
No Relationships to Disclose
 
Jeffrey H. Lee
No Relationships to Disclose
 
Brian Weston
No Relationships to Disclose
 
Manoop S. Bhutani
No Relationships to Disclose
 
Bruce D. Minsky
No Relationships to Disclose
 
David C. Rice
No Relationships to Disclose
 
Jun Eul Hwang
No Relationships to Disclose
 
Stephen Swisher
Consulting or Advisory Role - GlaxoSmithKline
Travel, Accommodations, Expenses - Memorial Sloan-Kettering Cancer Center
 
Wayne Lewis Hofstetter
No Relationships to Disclose
 
Mariela A. Blum
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Dipen M. Maru
No Relationships to Disclose
 
Jaffer A. Ajani
Honoraria - Bayer; Five Prime Therapeutics; Lilly/ImClone; Novartis
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Lilly/ImClone; MedImmune; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
Travel, Accommodations, Expenses - Bayer; Five Prime Therapeutics; Novartis
 
Ju-Seog Lee
No Relationships to Disclose